» Articles » PMID: 23787356

Systematic Review of Complications of Prostate Biopsy

Overview
Journal Eur Urol
Specialty Urology
Date 2013 Jun 22
PMID 23787356
Citations 396
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Prostate biopsy is commonly performed for cancer detection and management. The benefits and risks of prostate biopsy are germane to ongoing debates about prostate cancer screening and treatment.

Objective: To perform a systematic review of complications from prostate biopsy.

Evidence Acquisition: A literature search was performed using PubMed and Embase, supplemented with additional references. Articles were reviewed for data on the following complications: hematuria, rectal bleeding, hematospermia, infection, pain, lower urinary tract symptoms (LUTS), urinary retention, erectile dysfunction, and mortality.

Evidence Synthesis: After biopsy, hematuria and hematospermia are common but typically mild and self-limiting. Severe rectal bleeding is uncommon. Despite antimicrobial prophylaxis, infectious complications are increasing over time and are the most common reason for hospitalization after biopsy. Pain may occur at several stages of prostate biopsy and can be mitigated by anesthetic agents and anxiety-reduction techniques. Up to 25% of men have transient LUTS after biopsy, and <2% have frank urinary retention, with slightly higher rates reported after transperineal template biopsy. Biopsy-related mortality is rare.

Conclusions: Preparation for biopsy should include antimicrobial prophylaxis and pain management. Prostate biopsy is frequently associated with minor bleeding and urinary symptoms that usually do not require intervention. Infectious complications can be serious, requiring prompt management and continued work into preventative strategies.

Citing Articles

Combination of intrarectal heated lidocaine gel and periprostatic nerve block for pain control during transrectal ultrasound-guided prostate biopsy: A prospective randomized trial.

Kim J, Sohn D, Park B Investig Clin Urol. 2025; 66(2):130-136.

PMID: 40047126 PMC: 11885916. DOI: 10.4111/icu.20240312.


Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients with elevated PSA levels but negative MRI findings.

Peng Y, Wei C, Li Y, Zhao F, Liu Y, Jiang T BMC Urol. 2025; 25(1):42.

PMID: 40033313 PMC: 11874838. DOI: 10.1186/s12894-025-01719-5.


Development and validation of a nomogram model for predicting acute urinary retention after transrectal prostate biopsy.

Wang H, Li S, Wei S, Cao S, Huang X, Hu C Transl Androl Urol. 2025; 14(1):15-26.

PMID: 39974802 PMC: 11833541. DOI: 10.21037/tau-24-399.


A new ASAP Scoring System and Risk Table to predict second prostate biopsy outcomes.

Caner E, Serkan A, Neslihan K, Aysenur I Arch Med Sci. 2025; 20(6):1894-1901.

PMID: 39967942 PMC: 11831326. DOI: 10.5114/aoms/131789.


Retrospectively Quantified T2 Improves Detection of Clinically Significant Peripheral Zone Prostate Cancer.

Sun H, Wang L, Daskivich T, Qiu S, Lee H, Gao C Cancers (Basel). 2025; 17(3).

PMID: 39941750 PMC: 11816083. DOI: 10.3390/cancers17030381.